{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:44:07Z","timestamp":1785815047030,"version":"3.56.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Department of Science and Technology's Science and Engineering Research Board","award":["CRG\/2020\/000877"],"award-info":[{"award-number":["CRG\/2020\/000877"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01429-6","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:47:49Z","timestamp":1785811669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIPK2 exhibits context dependent dualistic effects and combinatorial inhibition of HIPK2-NLK-MAPK11 axis manifests synergism against gastric cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Aathithya","family":"Rangarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumoorthi","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Lakshminarayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"SunderSingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayavelu","family":"Subramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishnan Ayloor","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7869-4343","authenticated-orcid":false,"given":"Gopal","family":"Gopisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"37","key":"1429_CR1","doi-asserted-by":"publisher","first-page":"13545","DOI":"10.1074\/jbc.ra119.009725","volume":"294","author":"C Agnew","year":"2021","unstructured":"Agnew C, Liu L, Liu S, Xu W, You L, Yeung W, et al. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. J Biol Chem. 2021;294(37):13545\u201359. https:\/\/doi.org\/10.1074\/jbc.ra119.009725.","journal-title":"J Biol Chem"},{"key":"1429_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104274","volume":"85","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Meng D, Li F, Zhang X, Liu L, Zhu Y, et al. Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling. EBioMedicine. 2022;85:104274. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104274.","journal-title":"EBioMedicine"},{"issue":"1","key":"1429_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/cas.14691","volume":"112","author":"X Zheng","year":"2021","unstructured":"Zheng X, Pan Y, Chen X, Xia S, Hu Y, Zhou Y, et al. Inactivation of homeodomain-interacting protein kinase 2 promotes oral squamous cell carcinoma metastasis through inhibition of P53-dependent E-cadherin expression. Cancer Sci. 2021;112(1):117\u201332. https:\/\/doi.org\/10.1111\/cas.14691.","journal-title":"Cancer Sci"},{"issue":"14","key":"1429_CR4","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1038\/s41388-020-1190-y","volume":"39","author":"P Chen","year":"2020","unstructured":"Chen P, Duan X, Li X, Li J, Ba Q, Wang H. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1\u03b1. Oncogene. 2020;39(14):2863\u201376. https:\/\/doi.org\/10.1038\/s41388-020-1190-y.","journal-title":"Oncogene"},{"issue":"4","key":"1429_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4161\/cbt.13.4.18694","volume":"13","author":"C Nodale","year":"2012","unstructured":"Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, et al. HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. Cancer Biol Ther. 2012;13(4):198\u2013205. https:\/\/doi.org\/10.4161\/cbt.13.4.18694.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"1429_CR6","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.7150\/jca.52115","volume":"12","author":"N Duan","year":"2021","unstructured":"Duan N, Zhang W, Li Z, Sun L, Song T, Yu Z, et al. Overexpression of HIPK2 removes the transrepression of proapoptotic genes mediated by the CtBP1-p300-FOXO3a complex and increases the chemosensitivity in osteosarcoma cells. J Cancer. 2021;12(6):1826\u201337. https:\/\/doi.org\/10.7150\/jca.52115.","journal-title":"J Cancer"},{"issue":"3","key":"1429_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12603","volume":"52","author":"Y Qin","year":"2019","unstructured":"Qin Y, Hu Q, Ji S, Xu J, Dai W, Liu W, et al. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK\/cMyc axis in pancreatic cancer. Cell Prolif. 2019;52(3):e12603. https:\/\/doi.org\/10.1111\/cpr.12603.","journal-title":"Cell Prolif"},{"key":"1429_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1056427","author":"MJ Kwon","year":"2017","unstructured":"Kwon MJ, Kang SY, Nam ES, Cho SJ, Rho YS. HIPK2 overexpression and its prognostic role in human papillomavirus-positive tonsillar squamous cell carcinoma. Biomed Res Int. 2017. https:\/\/doi.org\/10.1155\/2017\/1056427.","journal-title":"Biomed Res Int"},{"issue":"6","key":"1429_CR9","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1002\/jcb28323","volume":"120","author":"F Liu","year":"2019","unstructured":"Liu F, Li N, Liu Y, Zhang J, Zhang J, Wang Z. Homeodomain interacting protein kinase-2 phosphorylates FOXM1 and promotes FOXM1-mediated tumor growth in renal cell carcinoma. J Cell Biochem. 2019;120(6):10391\u2013401. https:\/\/doi.org\/10.1002\/jcb28323.","journal-title":"J Cell Biochem"},{"issue":"3","key":"1429_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.18632\/oncotarget27871","volume":"12","author":"Y Dai","year":"2021","unstructured":"Dai Y, Kyoyama H, Yang YL, Wang Y, Liu S, Wang Y, et al. A novel isoform of homeodomain-interacting protein kinase-2 promotes YAP\/TEAD transcriptional activity in NSCLC cells. Oncotarget. 2021;12(3):173\u201384. https:\/\/doi.org\/10.18632\/oncotarget27871.","journal-title":"Oncotarget"},{"key":"1429_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110491","volume":"101","author":"A Conte","year":"2023","unstructured":"Conte A, Valente V, Paladino S, Pierantoni GM. HIPK2 in cancer biology and therapy: recent findings and future perspectives. Cell Signal. 2023;101:110491. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110491.","journal-title":"Cell Signal"},{"issue":"44","key":"1429_CR12","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1038\/onc.2017.221","volume":"36","author":"L Torrente","year":"2017","unstructured":"Torrente L, Sanchez C, Moreno R, Chowdhry S, Cabello P, Isono K, et al. Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses. Oncogene. 2017;36(44):6204\u201312. https:\/\/doi.org\/10.1038\/onc.2017.221.","journal-title":"Oncogene"},{"issue":"12","key":"1429_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3748\/wjg.v28.i12.1187","volume":"28","author":"M Ilic","year":"2022","unstructured":"Ilic M, Ilic I. Epidemiology of stomach cancer. World J Gastroenterol. 2022;28(12):1187\u2013203. https:\/\/doi.org\/10.3748\/wjg.v28.i12.1187.","journal-title":"World J Gastroenterol"},{"issue":"01","key":"1429_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0971-5851.81883","volume":"32","author":"RP Dikshit","year":"2011","unstructured":"Dikshit RP, Mathur G, Mhatre S, Yeole BB. Epidemiological review of gastric cancer in India. Indian J Med Paediatr Oncol. 2011;32(01):3\u201311. https:\/\/doi.org\/10.4103\/0971-5851.81883.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"1","key":"1429_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.21037\/jgo.2017.01.10","volume":"8","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, et al. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. J Gastrointest Oncol. 2017;8(1):148\u201363. https:\/\/doi.org\/10.21037\/jgo.2017.01.10.","journal-title":"J Gastrointest Oncol."},{"issue":"43","key":"1429_CR16","doi-asserted-by":"publisher","first-page":"12261","DOI":"10.3748\/wjg.v21.i43.12261","volume":"21","author":"SS Singh","year":"2015","unstructured":"Singh SS, Yap WN, Arfuso F, et al. Targeting the PI3K\/Akt signaling pathway in gastric carcinoma: a reality for personalized medicine? World J Gastroenterol. 2015;21(43):12261\u201373. https:\/\/doi.org\/10.3748\/wjg.v21.i43.12261.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1429_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01820-z","volume":"22","author":"A Marques-Ramos","year":"2023","unstructured":"Marques-Ramos A, Cervantes R. Expression of mTOR in normal and pathological conditions. Mol Cancer. 2023;22(1):112. https:\/\/doi.org\/10.1186\/s12943-023-01820-z.","journal-title":"Mol Cancer"},{"issue":"04","key":"1429_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/0971-5851.76197","volume":"31","author":"SH Advani","year":"2010","unstructured":"Advani SH. Targeting mTOR pathway: a new concept in cancer therapy. Indian J Med Paediatr Oncol. 2010;31(04):132\u20136. https:\/\/doi.org\/10.4103\/0971-5851.76197.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"1429_CR19","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"N Franken","year":"2006","unstructured":"Franken N, Rodermond H, Stap J, et al. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315\u20139. https:\/\/doi.org\/10.1038\/nprot.2006.339.","journal-title":"Nat Protoc"},{"key":"1429_CR20","unstructured":"Tong J. Transcription profiling by array of human gastric cancer cell lines and normal gastricmucosa. BioStudies. 2011. E-MEXP-2694.Retrieved from https:\/\/www.ebi.ac.uk\/biostudies\/arrayexpress\/studies\/E-MEXP-2694"},{"key":"1429_CR21","unstructured":"Rajkumar T , Rajkumar T. Gene expression studies in apparently normal paired normal and malignant gastric tissues. BioStudies. 2010. E-GEOD-17154. Retrieved from https:\/\/www.ebi.ac.uk\/biostudies\/arrayexpress\/studies\/E-GEOD-17154"},{"key":"1429_CR22","unstructured":"FlatbergA. Gene expression profiling of human gastric tumors and adjacent non-cancerous mucosa. BioStudies. 2014. E-MTAB-1338. Retrieved from https:\/\/www.ebi.ac.uk\/biostudies\/arrayexpress\/studies\/E-MTAB-1338"},{"key":"1429_CR23","unstructured":"Shao Q , Yao H , He J. Expression data from gastric cancer and paired normal tissues. BioStudies. 2016.E-GEOD-79973.Retrieved from https:\/\/www.ebi.ac.uk\/biostudies\/arrayexpress\/studies\/E-GEOD-79973"},{"issue":"6","key":"1429_CR24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/iub.1981","volume":"71","author":"E An","year":"2019","unstructured":"An E, Brognard J. Orange is the new black: kinases are the new master regulators of tumor suppression. IUBMB Life. 2019;71(6):738\u201348. https:\/\/doi.org\/10.1002\/iub.1981.","journal-title":"IUBMB Life"},{"issue":"3","key":"1429_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.molcel.2012.05.043","volume":"47","author":"RV Dur\u00e1n","year":"2012","unstructured":"Dur\u00e1n RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E, et al. Glutaminolysis activates RAG-MTORC1 signaling. Mol Cell. 2012;47(3):349\u201358. https:\/\/doi.org\/10.1016\/j.molcel.2012.05.043.","journal-title":"Mol Cell"},{"issue":"13","key":"1429_CR26","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1016\/j.celrep.2017.05.043","volume":"19","author":"N Emmanuel","year":"2017","unstructured":"Emmanuel N, Ragunathan S, Shan Q, Wang F, Giannakou A, Huser N, et al. Purine nucleotide availability regulates mTORC1 activity through the Rheb GTPase. Cell Rep. 2017;19(13):2665\u201380. https:\/\/doi.org\/10.1016\/j.celrep.2017.05.043.","journal-title":"Cell Rep"},{"issue":"2","key":"1429_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089176","volume":"9","author":"G Cozza","year":"2014","unstructured":"Cozza G, Zanin S, Determann R, Ruzzene M, Kunick C, Pinna LA. Synthesis and properties of a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2). PLoS ONE. 2014;9(2):e89176. https:\/\/doi.org\/10.1371\/journal.pone.0089176.","journal-title":"PLoS ONE"},{"issue":"3","key":"1429_CR28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3892\/ijo.2015.3100","volume":"47","author":"C Yang","year":"2015","unstructured":"Yang C, Zhang Y, Zhang Y, Zhang Z, Peng J, Li Z, et al. Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma. Int J Oncol. 2015;47(3):909\u201317. https:\/\/doi.org\/10.3892\/ijo.2015.3100.","journal-title":"Int J Oncol"},{"issue":"9","key":"1429_CR29","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1158\/1078-0432.CCR-20-2961","volume":"27","author":"X Wang","year":"2021","unstructured":"Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, et al. Therapeutic targeting of nemo-like kinase in primary and acquired endocrine-resistant breast cancer. Clin Cancer Res. 2021;27(9):2648\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2961.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1429_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207524","volume":"21","author":"O Roche","year":"2020","unstructured":"Roche O, Fern\u00e1ndez-Aroca DM, Arconada-Luque E, Garc\u00eda-Flores N, Mellor LF, Ruiz-Hidalgo MJ, et al. P38\u03b2 and cancer: the beginning of the road. Int J Mol Sci. 2020;21(20):7524. https:\/\/doi.org\/10.3390\/ijms21207524.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1429_CR31","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.3390\/cimb44100335","volume":"44","author":"D Duarte","year":"2022","unstructured":"Duarte D, Guerreiro I, Vale N. Novel strategies for cancer combat: drug combination using repurposed drugs induces synergistic growth inhibition of MCF-7 breast and HT-29 colon cancer cells. Curr Issues Mol Biol. 2022;44(10):4930\u201349. https:\/\/doi.org\/10.3390\/cimb44100335.","journal-title":"Curr Issues Mol Biol"},{"key":"1429_CR32","doi-asserted-by":"publisher","first-page":"27511","DOI":"10.18632\/oncotarget.8484","volume":"7","author":"B Davaadelger","year":"2016","unstructured":"Davaadelger B, Duan L, Perez RE, Gitelis S, Maki CG. Crosstalk between the IGF-1R\/AKT\/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016;7:27511\u201326.","journal-title":"Oncotarget"},{"key":"1429_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.87344","volume":"12","author":"A Semlali","year":"2022","unstructured":"Semlali A, Papadakos S, Contant C, Zouaoui I, Rouabhia M. Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1\/2, NF-\u03baB and beta-catenin pathways. Front Oncol. 2022;12:873447. https:\/\/doi.org\/10.3389\/fonc.2022.87344.","journal-title":"Front Oncol"},{"key":"1429_CR34","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.2147\/cmar.s175681","volume":"10","author":"Y He","year":"2018","unstructured":"He Y, Xue C, Yu Y, Chen J, Chen X, Ren F, et al. CD44 is overexpressed and correlated with tumor progression in gallbladder cancer. Cancer Manag Res. 2018;10:3857\u201365. https:\/\/doi.org\/10.2147\/cmar.s175681.","journal-title":"Cancer Manag Res"},{"issue":"13","key":"1429_CR35","doi-asserted-by":"publisher","first-page":"11465","DOI":"10.18632\/oncotarget.3410","volume":"6","author":"S McFarlane","year":"2015","unstructured":"McFarlane S, Coulter JA, Tibbits P, O\u2019Grady A, McFarlane C, Montgomery N, et al. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget. 2015;6(13):11465\u201376. https:\/\/doi.org\/10.18632\/oncotarget.3410.","journal-title":"Oncotarget"},{"issue":"1","key":"1429_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3892\/ol.2016.5432","volume":"13","author":"T Watanabe","year":"2017","unstructured":"Watanabe T, Okumura T, Hirano K, Yamaguchi T, Sekine S, Nagata T, et al. Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer. Oncol Lett. 2017;13(1):281\u20138. https:\/\/doi.org\/10.3892\/ol.2016.5432.","journal-title":"Oncol Lett"},{"issue":"2","key":"1429_CR37","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1053\/j.gastro.2013.05.002","volume":"145","author":"AI Thaker","year":"2013","unstructured":"Thaker AI, Rao MS, Bishnupuri KS, Kerr TA, Foster L, Marinshaw JM, et al. IDO1 metabolites activate \u03b2-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology. 2013;145(2):416-25.e254. https:\/\/doi.org\/10.1053\/j.gastro.2013.05.002.","journal-title":"Gastroenterology"},{"issue":"4","key":"1429_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccr.2011.08.016","volume":"20","author":"N Zhang","year":"2011","unstructured":"Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, et al. FoxM1 promotes \u03b2-catenin nuclear localization and controls WNT target-gene expression and glioma tumorigenesis. Cancer Cell. 2011;20(4):427\u201342. https:\/\/doi.org\/10.1016\/j.ccr.2011.08.016.","journal-title":"Cancer Cell"},{"issue":"9","key":"1429_CR39","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1007\/s13277-015-3415-1","volume":"36","author":"L Dong","year":"2015","unstructured":"Dong L, Deng J, Sun ZM, Pan AP, Xiang XJ, Zhang L, et al. Interference with the \u03b2-catenin gene in gastric cancer induces changes to the miRNA expression profile. Tumor Biol. 2015;36(9):6973\u201383. https:\/\/doi.org\/10.1007\/s13277-015-3415-1.","journal-title":"Tumor Biol"},{"issue":"10","key":"1429_CR40","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/jcb.24842","volume":"115","author":"M Tan","year":"2014","unstructured":"Tan M, Gong H, Zeng Y, Tao L, Wang J, Jiang J, et al. Downregulation of homeodomain-interacting protein kinase-2 contributes to bladder cancer metastasis by regulating WNT signaling. J Cell Biochem. 2014;115(10):1762\u20137. https:\/\/doi.org\/10.1002\/jcb.24842.","journal-title":"J Cell Biochem"},{"key":"1429_CR41","doi-asserted-by":"publisher","DOI":"10.23736\/s2724-5985.21.02969-7","author":"N Zhang","year":"2022","unstructured":"Zhang N, Meng H, Tian A, Chen Y. Expression of HIPK2 in gastric cancer and its effects on cell function in vitro. Minerva Gastroenterol. 2022. https:\/\/doi.org\/10.23736\/s2724-5985.21.02969-7.","journal-title":"Minerva Gastroenterol"},{"issue":"4","key":"1429_CR42","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.bbrc.2010.03.099","volume":"394","author":"EA Kim","year":"2010","unstructured":"Kim EA, Kim JE, Sung KS, Choi DW, Lee BJ, Choi CY. Homeodomain-interacting protein kinase 2 (HIPK2) targets \u03b2-catenin for phosphorylation and proteasomal degradation. Biochem Biophys Res Commun. 2010;394(4):966\u201371. https:\/\/doi.org\/10.1016\/j.bbrc.2010.03.099.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"1429_CR43","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.7150\/jca.90170","volume":"15","author":"P Li","year":"2024","unstructured":"Li P, Zhang Z, Sun P. DOT1L promotes expression of CD44 through the Wnt\/\u03b2-catenin signaling pathway in early gastric carcinoma. J Cancer. 2024;15(8):2276\u201391. https:\/\/doi.org\/10.7150\/jca.90170.","journal-title":"J Cancer"},{"issue":"2","key":"1429_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055522","volume":"8","author":"HS Lee","year":"2013","unstructured":"Lee HS, Park CK, Oh E, Erkin \u00d6C, Jung HS, Cho MH, et al. Low SP1 expression differentially affects intestinal-type compared with diffuse-type gastric adenocarcinoma. PLoS ONE. 2013;8(2):e55522. https:\/\/doi.org\/10.1371\/journal.pone.0055522.","journal-title":"PLoS ONE"},{"issue":"1","key":"1429_CR45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8(1):375. https:\/\/doi.org\/10.1038\/s41392-023-01608-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"1429_CR46","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/ijms17101638","volume":"17","author":"Y Kuwano","year":"2016","unstructured":"Kuwano Y, Nishida K, Akaike Y, Kurokawa K, Nishikawa T, Masuda K, et al. Homeodomain-interacting protein kinase-2: a critical regulator of the DNA damage response and the epigenome. Int J Mol Sci. 2016;17(10):1638. https:\/\/doi.org\/10.3390\/ijms17101638.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1429_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3727\/096504016X14772410356982","volume":"26","author":"Y Li","year":"2018","unstructured":"Li Y, Yan X, Ren L, Li Y. MiR-644a inhibits cellular proliferation and invasion via suppression of CtBP1 in gastric cancer cells. Oncol Res. 2018;26(1):1\u20138. https:\/\/doi.org\/10.3727\/096504016X14772410356982.","journal-title":"Oncol Res"},{"issue":"5","key":"1429_CR48","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1158\/1541-7786.MCR-21-0628","volume":"20","author":"M Di Segni","year":"2022","unstructured":"Di Segni M, Virdia I, Verdina A, Amoreo CA, Baldari S, Toietta G, et al. HIPK2 cooperates with KRAS signaling and associates with colorectal cancer progression. Mol Cancer Res MCR. 2022;20(5):686\u201398. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0628.","journal-title":"Mol Cancer Res MCR"},{"issue":"7","key":"1429_CR49","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1101\/gad.1170604","volume":"18","author":"C Kanei-Ishii","year":"2004","unstructured":"Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J, Nomura T, Ishitani T, Kishida S, et al. Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2 and NLK. Genes Dev. 2004;18(7):816\u201329. https:\/\/doi.org\/10.1101\/gad.1170604.","journal-title":"Genes Dev"},{"issue":"4","key":"1429_CR50","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1021\/acsptsci.9b00042","volume":"2","author":"PS Thakuri","year":"2019","unstructured":"Thakuri PS, Gupta M, Joshi R, Singh S, Tavana H. Synergistic inhibition of kinase pathways overcomes resistance of colorectal cancer spheroids to cyclic targeted therapies. ACS Pharmacol Transl Sci. 2019;2(4):275\u201384. https:\/\/doi.org\/10.1021\/acsptsci.9b00042.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"8","key":"1429_CR51","doi-asserted-by":"publisher","first-page":"859","DOI":"10.18632\/oncotarget.27930","volume":"12","author":"E Montaudon","year":"2021","unstructured":"Montaudon E, Botty RE, Vacher S, D\u00e9as O, Naguez A, Chateau-Joubert S, et al. High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC. Oncotarget. 2021;12(8):859\u201372. https:\/\/doi.org\/10.18632\/oncotarget.27930.","journal-title":"Oncotarget"},{"issue":"1","key":"1429_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00578-4","volume":"6","author":"R Zhu","year":"2021","unstructured":"Zhu R, Li L, Nguyen B, Seo J, Wu M, Seale T, et al. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther. 2021;6(1):186. https:\/\/doi.org\/10.1038\/s41392-021-00578-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1429_CR53","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1021\/acs.jmedchem.2c01887","volume":"66","author":"P Grygier","year":"2023","unstructured":"Grygier P, Pustelny K, Nowak J, Golik P, Popowicz GM, Plettenburg O, et al. Silmitasertib (CX-4945), a clinically used CK2-kinase inhibitor with additional effects on GSK3\u03b2 and DYRK1A kinases: a structural perspective. J Med Chem. 2023;66(6):4009\u201324. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01887.","journal-title":"J Med Chem"},{"key":"1429_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2025.105422","volume":"52","author":"RJ Bloch","year":"2025","unstructured":"Bloch RJ, Traficante M, Mariot V, Dumonceaux J. The recent clinical trial of losmapimod for the treatment of facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2025;52:105422. https:\/\/doi.org\/10.1016\/j.nmd.2025.105422.","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"1429_CR55","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.18632\/oncotarget.790","volume":"3","author":"S Chung","year":"2012","unstructured":"Chung S, Suzuki H, Miyamoto T, Takamatsu N, Tatsuguchi A, Ueda K, et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012;3(12):1629\u201340. https:\/\/doi.org\/10.18632\/oncotarget.790.","journal-title":"Oncotarget"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01429-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01429-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01429-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:47:52Z","timestamp":1785811672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01429-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01429-6","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"121"}}